texas oncology more breakthroughs. more victories
Some of our cancer centers are experiencing issues.  View More Important Notifications x

Baylor Charles A. Sammons Research & Clinical Trials

Baylor Charles A. Sammons Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Innovative Clinical Trial Center (Expand)

Myelofibrosis

A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis (M20-247)

Phase: Ib

Solid Tumors

A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

Phase: Phase I/II

A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Phase: II

An Open Label, Multicenter, Long-Term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies

Phase: III

Texas Oncology-Baylor Charles A. Sammons Cancer Center (Expand)

Anal Cancer

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read Moreabout STAR Ph3 Carbo/Pac NCMGA00012 MSCC

Phase: III

Biliary Cancer

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

Bladder Cancer

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read Moreabout STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

Phase: I/II

Blood Cancer

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Breast Cancer

Ph3 GDC-9545+ Palbo +/- Letro HER2- BC

(BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER Read Moreabout Ph3 GDC-9545+ Palbo +/- Letro HER2- BC

Phase: III

PH3 Enobosarm AR+ER+HER2- Fulv

(V3002401) ARTEST - A Randomized Crossover Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥ 40% Who Have Shown Previous Disease Progression onBeen Previously Treated With a Nonsteroidal Aromatase Inhibitor FulvestrantSERD and CDK 4/6 inhibitorAromatase Inhibitor Fulvestrant and CDK 4/6 inhibitor Read Moreabout PH3 Enobosarm AR+ER+HER2- Fulv

Phase: III

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

STAR Ph2 Trila Sacit Gove TNBC

A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213) Read Moreabout STAR Ph2 Trila Sacit Gove TNBC

Phase: II

Ph3 Gem Carbo BC Preserve 2

A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208) Read Moreabout Ph3 Gem Carbo BC Preserve 2

Phase: III

PH3 Tras Deru HER2- BC

A Phase 3 Randomized Multi-center Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001) Read Moreabout PH3 Tras Deru HER2- BC

Phase: III

Ph3 GDC-9545 ER+ HER2- BC (lidERA)

A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)

Phase: III

Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001) Read Moreabout Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

Phase: III

Ph3 HER2+/ER+ BC

A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC

Phase: III

Ph3 HER2/neu BC (FLAMINGO-01)

A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)

Phase: III

Ph3 Sac Gov Pemb vs PC BC

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC

Phase: III

Ph3 Sac GOv vs PC BC

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC

Phase: III

Registry study with Breast Cancer Index

Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT) Read Moreabout Registry study with Breast Cancer Index

Phase: IV

Ph1a/1b LY3484356 Abem ER+ HER2-

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-

Phase: I

Ph3 LY3484356 ER+ HER2- BC

EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC) Read Moreabout Ph3 LY3484356 ER+ HER2- BC

Phase: III

PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA

EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202) Read Moreabout PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA

Phase: II

Ph3 Nira Her2- triple- BC ctDNA (ZEST)

GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY Read Moreabout Ph3 Nira Her2- triple- BC ctDNA (ZEST)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph 1b2 LIV1A+Pembro 1L mTNBC

Single Arm Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (SGNLVA-002) Read Moreabout Ph 1b2 LIV1A+Pembro 1L mTNBC

Phase: I/II

Carcinoid

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read Moreabout STAR Ph3 Carbo/Pac NCMGA00012 MSCC

Phase: III

Cervical Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

Colon Cancer

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

STAR Ph3 MRTX849 Cetux KRAS G12C CC

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010) Read Moreabout STAR Ph3 MRTX849 Cetux KRAS G12C CC

Phase: III

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

Colorectal Cancer

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Endometrial Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064) Read Moreabout Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

Phase: III

Ph1a/1b LY3484356 Abem ER+ HER2-

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-

Phase: I

Esophageal Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

PH2/3 Tuca Trast vs Placebo HER2+ GEC

MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022) Read Moreabout PH2/3 Tuca Trast vs Placebo HER2+ GEC

Phase: II/III

Fallopian Tube Cancer

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Gall Bladder Cancer

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

Gastric Cancer

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

PH2/3 Tuca Trast vs Placebo HER2+ GEC

MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022) Read Moreabout PH2/3 Tuca Trast vs Placebo HER2+ GEC

Phase: II/III

Head and Neck

A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Pep-tides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Sub-jects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection

Phase: II

Head and Neck Cancer

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC

A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Hematologic

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Idiopathic Thrombocytopenia

Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Phase: IV

Leukemia

A Phase 1b/2 study of the safety, PK, PD and preliminary efficacy of the FLT3 inhibitor gilteritinib, in combination with the selective SYK inhibitor lanraplenib (KB-9876), in patients with FLT3-mutated relapsed or refractory AML

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph1b/2 Siremadlin + Vene + Azac AML

A phase Ib/II open label dose confirmation proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201) Read Moreabout Ph1b/2 Siremadlin + Vene + Azac AML

Phase: I/II

Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS

A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101) Read Moreabout Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS

Phase: I/II

Ph3 Ascim vs PC TKI new dx Ph+ CML

A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301) Read Moreabout Ph3 Ascim vs PC TKI new dx Ph+ CML

Phase: III

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Phase: III

STAR Ph3b ABL001 in CML-CP +/-T315i

An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04) Read Moreabout STAR Ph3b ABL001 in CML-CP +/-T315i

Phase: III/IV

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)

Lung Cancer

Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

STAR Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout STAR Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II

STAR Ph3 Ami Laz EGFR-mut NSCLC

A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC

Phase: III

PH3 Nira Pembro Stg 3/4 NSCLC

A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400) Read Moreabout PH3 Nira Pembro Stg 3/4 NSCLC

Phase: III

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Phase: III

STAR PH3 EGFRm stage2/3b NSCLC

A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

Ph2 Tomivosertib+Anti-PD-L1 NSCLC

A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011) Read Moreabout Ph2 Tomivosertib+Anti-PD-L1 NSCLC

Phase: II

STAR PH3 JNJ-61186372 Peme EGFR NSCLC

A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001) Read Moreabout STAR PH3 JNJ-61186372 Peme EGFR NSCLC

Phase: III

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Phase: III

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Phase: II

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Phase: PLT

Ph2 Nap r/r NSCLC

NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER Read Moreabout Ph2 Nap r/r NSCLC

Phase: II

Ph3 SAR408701 vs Doce NSCLC CEACAM5+

Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858) Read Moreabout Ph3 SAR408701 vs Doce NSCLC CEACAM5+

Phase: III

STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C

RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies Read Moreabout STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C

Phase: II

Lymphomas

STAR BV in pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL

Phase: II

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Lonca-R DLBCL

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203) Read Moreabout Ph2 Lonca-R DLBCL

Phase: II

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: II/III

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Phase: III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

A Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Phase: II

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Melanoma

A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (PISCES)

Phase: II

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

A Phase 3, Randomized ,Double-blind Study of Adjuvant Immunotherapy with Relalimab+Nivolumab versus Nivolumab after Complete Resection of Stage III-IV Melanoma

Phase: III

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Phase: II

PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Multiple Myeloma

A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Phase: Ib/II

Myelodysplasia

Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Treatment-naïve, RARA-positive Adult Participants with Higher-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS

A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101) Read Moreabout Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS

Phase: I/II

Ph2 IV MBG453 MDS IPSS-R

Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US) CMBG453B1US01 Read Moreabout Ph2 IV MBG453 MDS IPSS-R

Phase: II

Myelofibrosis

A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis (M20-247)

Phase: Ib

STAR Ph2 Selinexor vs PC MF

A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035) Read Moreabout STAR Ph2 Selinexor vs PC MF

Phase: II

A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

STAR Ph3 Navi Ruxo Myelofibrosis

M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1) Read Moreabout STAR Ph3 Navi Ruxo Myelofibrosis

Phase: III

Myelomas

PH3 Dara/Len vs Len NDMM

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021) Read Moreabout PH3 Dara/Len vs Len NDMM

Phase: III

Ph2 Magrolimab r/r MM

GS-US-558-5915: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma Read Moreabout Ph2 Magrolimab r/r MM

Phase: II

Neuroendocrine Tumors

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

Ovarian Cancer

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph1b/2 XMT-1536 ST NaPi2b

A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048) Read Moreabout Ph1b/2 XMT-1536 ST NaPi2b

Phase: II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

STAR Ph2 VS-6766 Fak-Inhib LGSOC

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC

Phase: II

PH3 Alpe BYL719 Olap BRCA OC

EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301) Read Moreabout PH3 Alpe BYL719 Olap BRCA OC

Phase: III

Pancreatic Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC

A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301) Read Moreabout Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC

Phase: III

PANOVA-3: 1L Gemcit + nab-pac pancreatic

PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read Moreabout PANOVA-3: 1L Gemcit + nab-pac pancreatic

Phase: III

Peritoneal Cancer

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Prostate Cancer

STAR PH3 Nirap Abira HRR mCSPC

A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002) Read Moreabout STAR PH3 Nirap Abira HRR mCSPC

Phase: III

STAR PH3 Abi+/-Capi mHSPC CAPItello-281

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281

Phase: III

Rectal Cancer

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

Renal Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Sarcoma

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

Skin Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Solid Tumors

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors.

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors

Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read Moreabout Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

A Phase 1-2 Dose-Escalation and Expansion Study ofST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

A Phase I, First-in-human, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 alone and in combination with Ipilimumab and Nivolumab

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

Phase: Phase I/II

A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Phase: II

An Open Label, Multicenter, Long-Term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies

Phase: III

An Open-Label Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of TAK-573 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced or Metastatic Solid Tumors”

Ph1b/2 Surufatinib + Tislelizumab ST

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1) Read Moreabout Ph1b/2 Surufatinib + Tislelizumab ST

Phase: I/II

Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932) Read Moreabout Ph2 Tumor-Agnostic Precision TAPISTRY

Phase: II

Squamous Cell Cancer

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma

Phase: III

Cemiplimab Survivorship Epidemiology (CASE) Study

Phase: IV

Urothelial Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II

STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read Moreabout STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

Phase: I/II

Uterine Cancer

Ph2 Basket Tucat+Tras ST HER2 Alt

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt

Phase: II